Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYGM | P11217 | 3/20 | 0.70 |
| ▸ | TK2 | O00142 | 4/20 | 0.65 |
| ▸ | TYMP | P19971 | 2/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | ALB | P02768 | 1/20 | 0.60 |
| ▸ | POLB | P06746 | 1/20 | 0.60 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.60 |
| ▸ | BLM | P54132 | 1/20 | 0.60 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.60 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.60 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.60 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2786143 | 1.00 | PYGM (0.70) | PYGMTK2TYMPALDH1A1LMNA | |
| SCHEMBL10812613 | 1.00 | PYGM (0.70) | PYGMTK2TYMPALDH1A1LMNA | |
| SCHEMBL12103839 | 1.00 | PYGM (0.70) | PYGMTK2TYMPALDH1A1LMNA | |
| SCHEMBL453142 | 1.00 | PYGM (0.70) | PYGMTK2TYMPALDH1A1LMNA | |
| SCHEMBL14388592 | 1.00 | PYGM (0.70) | PYGMTK2TYMPALDH1A1LMNA | |
| SCHEMBL22143517 | 1.00 | PYGM (0.70) | PYGMTK2TYMPALDH1A1LMNA | |
| SCHEMBL1983444 | 1.00 | PYGM (0.70) | PYGMTK2TYMPALDH1A1LMNA | |
| SCHEMBL2583974 | 1.00 | PYGM (0.70) | PYGMTK2TYMPALDH1A1LMNA | |
| SCHEMBL10340724 | 1.00 | PYGM (0.70) | PYGMTK2TYMPALDH1A1LMNA | |
| SCHEMBL10815567 | 1.00 | PYGM (0.70) | PYGMTK2TYMPALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 11243 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4747386-A1 | DOUBLE-STRANDED OLIGONUCLEOTIDE AGENTS AND USES THEREOF | Bisirna Therapeutics Pte. Ltd. (SG) | 2026-05-27 | — | — | EP | claimed |
| WO-2026103936-A1 | CHEMICALLY MODIFIED CIRCULAR RNA MOLECULE, PREPARATION METHOD THEREFOR, AND USE THEREOF | 上海元码智药生物技术有限公司 | 2026-05-21 | — | — | WO | claimed |
| CN-122060818-A | Chemically modified circular RNA molecules, methods of making and uses thereof | 上海元码智药生物技术有限公司 | 2026-05-19 | — | — | CN | claimed |
| US-12630851-B2 | Polynucleotide modification methods | OXFORD NANOPORE TECHNOLOGIES PLC (GB) | 2026-05-19 | — | — | US | claimed |
| EP-4739343-A2 | CIRCULAR RNA VACCINES FOR SEASONAL FLU AND METHODS OF USES | Shanghai Circode Biomed Co., Ltd (CN) | 2026-05-13 | — | — | EP | claimed |
| CN-122029278-A | Constructs, methods and uses for the preparation of circular RNAs | 上海环码生物医药有限公司 | 2026-05-12 | — | — | CN | claimed |
| CN-122005867-A | Use of a substance that increases IRF5 content in a subject in a product of pulmonary fibrosis | 广州国家实验室 | 2026-05-12 | — | — | CN | claimed |
| US-20260125673-A1 | ARTIFICIAL POLYNUCLEOTIDES FOR EXPRESSING PROTEINS | CERTEST BIOTEC S L (ES) | 2026-05-07 | — | — | US | claimed |
| WO-2026089123-A1 | NOVEL NUCLEIC ACID CONSTRUCT COMPRISING POLY(A) TAIL HAVING SECONDARY OR TERTIARY STRUCTURE AND CONTAINING NON-A SEQUENCE AT TERMINUS, AND USES THEREOF | 삼성바이오로직스 주식회사 | 2026-04-30 | — | — | WO | claimed |
| WO-2026090596-A1 | SYSTEMS AND DEVICES FOR ADMINISTRATION OF RNA VACCINES AND METHODS OF USE THEREOF | PIEZO THERAPEUTICS, INC. (US) | 2026-04-30 | — | — | WO | claimed |
| US-5861493-A | ALKYLATING WITH ALCOHOL IN PRESENCE OF LEWIS ACID; PREPARING OLIGONUCLEOTIDES | ISIS PHARMACEUTICALS, INC. (US) | 1999-01-19 | — | — | US | claimed |
| CN-1190656-A | Process for separating thymidine from mixture | HUADONG SCIENCE & ENGINEERING (CN) | 1998-08-19 | — | — | CN | claimed |
| EP-0813539-A1 | IMPROVED PROCESS FOR THE SYNTHESIS OF 2'-O-SUBSTITUTED PYRIMIDINES AND OLIGOMERIC COMPOUNDS THEREFROM | ISIS PHARMACEUTICALS, INC. (US) | 1997-12-29 | — | — | EP | claimed |
| EP-0795029-A1 | CHEMICAL LABELLING OF OBJECTS | Pabio (NO) | 1997-09-17 | — | — | EP | claimed |
| CN-1154111-A | New lipid esters of nucleoside monophosphates and their use as immunosuppressive drugs | BOEHRINGER MANNHEIM GMBH (DE) | 1997-07-09 | — | — | CN | claimed |
| EP-0763049-A1 | NEW LIPID ESTERS OF NUCLEOSIDE MONOPHOSPHATES AND THEIR USE AS IMMUNOSUPPRESSIVE DRUGS | Roche Diagnostics GmbH (DE) | 1997-03-19 | — | — | EP | claimed |
| WO-1996027606-A1 | IMPROVED PROCESS FOR THE SYNTHESIS OF 2'-O-SUBSTITUTED PYRIMIDINES AND OLIGOMERIC COMPOUNDS THEREFROM | ISIS PHARMACEUTICALS, INC. (US) | 1996-09-12 | — | — | WO | claimed |
| US-5547857-A | Process for producing 5-methyluridine and purification by sedimentation velocity | AJINOMOTO CO., INC. (JP) | 1996-08-20 | — | — | US | claimed |
| WO-1996017954-A1 | CHEMICAL LABELLING OF OBJECTS | PABIO (DK) | 1996-06-13 | — | — | WO | claimed |
| WO-1995032984-A1 | NEW LIPID ESTERS OF NUCLEOSIDE MONOPHOSPHATES AND THEIR USE AS IMMUNOSUPPRESSIVE DRUGS | BOEHRINGER MANNHEIM GMBH (DE) | 1995-12-07 | — | — | WO | claimed |